Pacritinib clinical trials
Also written SB1518 and Vonjo.
How each study uses pacritinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pacritinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Feb 2022 · VONJO · NDA 208712 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2026 (10)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 32
CTI BioPharma (10) · S*BIO (4) · Washington University School of Medicine (4) · National Cancer Institute (NCI) (3) · University of Michigan Rogel Cancer Center (3) · M.D. Anderson Cancer Center (3) · Swedish Orphan Biovitrum (2) · University of Washington (2)
Often tested with
Tested in the same studies.
Azacitidine (4) · Decitabine (2) · Ruxolitinib (2) · Luspatercept (1) · Venetoclax (1) · Selinexor (1) · BTK Inhibitor (1) · Fedratinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test pacritinib.
- Dec 2026Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedEarly Phase 1 · University of Kansas Medical Center
- Dec 2026A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Phase 2 · Swedish Orphan Biovitrum
- Mar 2027Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromePhase 1 · Washington University School of Medicine
- Jul 2027Pacritinib in CMMLPhase 1/2 · Douglas Tremblay
- Jul 2027Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Phase 1/2 · National Cancer Institute (NCI)
- Nov 2027Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsPhase 2 · University of Michigan Rogel Cancer Center
- Nov 2027Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsPhase 2 · University of Washington
Studies
Open first, then newest update. How each study uses pacritinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 50
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingPhase 1/2National Cancer Institute (NCI)NCT06303193Written as pacritinib
- Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and ThrombocytopeniaNot yet recruitingPhase 2Case Comprehensive Cancer CenterNCT07936201Written as Pacritinib
- Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05531786Written as Pacritinib
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasRecruitingPhase 2John MascarenhasNCT07447817Written as Pacritinib
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Pacritinib
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)RecruitingPhase 2Swedish Orphan BiovitrumNCT06782373Written as Pacritinib
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT06052618Written as Pacritinib
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 1City of Hope Medical CenterNCT06675123Written as Pacritinib
- Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingPhase 2Grupo Español de Enfermedades Mieloproliferativas Crónicas PH NegativasNCT07394153Written as Pacritinib
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT04282187Written as Pacritinib
- Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling InhibitorsRecruitingPhase 2Medical College of WisconsinNCT07226713Written as Pacritinib
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT07148947Written as Pacritinib
- Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaRecruitingPhase 2TheradexNCT07033598Written as Pacritinib
- Pacritinib in CMMLRecruitingPhase 1/2Douglas TremblayNCT06159491Written as Pacritinib
- Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromeRecruitingPhase 1Washington University School of MedicineNCT06538181Written as Pacritinib
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingEarly Phase 1University of Kansas Medical CenterNCT06414681Written as Pacritinib
- Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT04858256Written as Pacritinib
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingPhase 2Shayna Sarosiek, MDNCT06986174Written as Pacritinib
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingPhase 1Fox Chase Cancer CenterNCT06218628Written as pacritinib
- Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnPhase 1/2Thomas Jefferson UniversityNCT07387354Written as Pacritinib
See all 50 studies that test pacritinib →
Given beside what is tested · 3 — pacritinib is usual care or a partner of the new treatment
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingPhase 2Karyopharm Therapeutics IncNCT05980806Written as Pacritinib
- Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 MutationsCompletedPhase 1Bhavana BhatnagarNCT02323607Written as Pacritinib
- Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedPhase 2Weill Medical College of Cornell UniversityNCT02532010Written as Pacritinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasOct 27, 2026NCT07447817
Newly registered1
Codes
What other systems call pacritinib · ClinicalTrials.gg INT005890
- MeSH (NLM) C561234pacritinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G22N65IL3OPACRITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2595243One source FDA
- Wikidata Q3888693pacritinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78837PacritinibOne source FDA
- DrugBank DB11697One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561234 | pacritinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G22N65IL3O | PACRITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2595243 | — | One source FDA |
| Wikidata | Q3888693 | pacritinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78837 | Pacritinib | One source FDA |
| DrugBank | DB11697 | — | One source Wikidata |
Also registered as pacritinib citrate (UNII VJ2PH4NXX7 · RxNorm 2595242).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.